DICE Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
DICE Therapeutics, a biopharmaceutical company focusing on oral therapeutics for chronic diseases, will present at the Bank of America Securities 2022 Healthcare Conference on May 11, 2022, at 1:20 p.m. PT. The event will be accessible via a live and archived webcast on the Company’s website.
DICE is leveraging its DELSCAPE platform to develop oral candidates targeting IL-17, α4ß7 integrin, and αVß1/αVß6 integrin for conditions in immunology, inflammatory bowel disease, and idiopathic pulmonary fibrosis, aiming for comparable efficacy to systemic biologics.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced that management will present at the Bank of America Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 1:20 p.m. PT / 4:20 p.m. ET.
A live and archived webcast of the presentation can be accessed under “Events & Presentations” on the Investors section of the Company's website. The archived webcast will be available on the Company’s website for 90 days after the event.
About DICE Therapeutics, Inc.
DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidates are oral antagonists of the pro-inflammatory signaling molecule, IL-17, which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.
Contact:
Katie Engleman, 1AB
katie@1abmedia.com
FAQ
When is DICE Therapeutics presenting at the 2022 Healthcare Conference?
Where can I watch the DICE Therapeutics presentation?
What is DICE Therapeutics focused on developing?
What technology platform does DICE Therapeutics use?
What are the lead therapeutic candidates of DICE Therapeutics?
